Avonex Combination Trial in relapsing—remitting MS: rationale,design and baseline data

Abstract

Objective To review the rationale, design and baseline data of the Avonex Combination Trial (ACT), an investigator-run study of intramuscular interferon beta-1a (IM IFNβ-1a) combined with methotrexate (MTX) and/or IV methylprednisolone (IVMP) in relapsing—remitting multiple sclerosis (RRMS) patients with continued disease activity on IM IFNβ-1a monotherapy.

Methods Eligibility criteria included RRMS, Expanded Disability Status Scale score 0—5.5, and ≥1 relapse or gadolinium-enhancing MRI lesion in the prior year while on IM IFNβ-1a monotherapy. Subjects continued IFNβ-1a 30 mcg IM weekly and were randomized in a 2 × 2 factorial design to adjunctive weekly placebo or MTX 20 mg PO, with or without IVMP 1000 mg/day for three days every other month. ACT was industry-supported, and collaboratively designed and governed by an Investigator Steering Committee with independent Advisory and Data Safety Monitoring Committees. Study operations, MRI analysis and aggregated data were managed by the Cleveland Clinic MS Academic Coordinating Center.

Results In total 313 subjects were enrolled with clinical and MRI characteristics typical of RRMS. Most subjects (86.9%) qualified with a clinical relapse, with or without an enhancing MRI lesion, in the preceding year. At baseline, 21.4% had enhancing lesions, and 5.1% had anti-IFNβ neutralizing antibodies. ACT's management and operational structures functioned well.

Conclusion This study provides an innovative model for academic—industry collaborative MS research and will enhance understanding of the utility of combination therapy for RRMS patients with continued disease activity on an established first-line treatment. Multiple Sclerosis 2008; 14: 370—382. http://msj.sagepub.com

Keywords

clinical trial interferon beta-1a methotrexate methylprednisolone multiple sclerosis

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-61.

The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-85.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996 ; 39: 285-94.

PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-504.

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J. , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology 1995; 45: 1268-76.

European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-97.

Hartung HP , Gonsette R. , the MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomised, multicentre trial . Lancet 2002 ; 360: 2018-25.

Krapf H. , Morrissey SP , Zenker O. , Zwingers T. , Gonsette R. , Hartung HP et al. Effect of mitoxantrone on MRI in progressive MS. Results of the MIMS trial . Neurology 2005; 65: 690-95.

Polman CH , O'Connor PW , Hardova E. , Hutchinson M. , Kappos L. , Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis . N Engl J Med 2006; 354: 899-910.

10.

Rudick RA , Stuart WH , Calabresi PA , Confavreux C. , Galetta SL , Radue EW et al. Natalizumab plus Interferon beta-1a for relapsing multiple sclerosis . N Engl J Med 2006; 354: 911-23.

11.

Cohen JA , Confavreux C. Combination therapy in multiple sclerosis. In Cohen JA , Rudick RA eds. Multiple sclerosis therapeutics, 3rd edition. London: Informa Healthcare, 2007 : 681-97.

12.

McDonald WI , Compston DA , Edan G. , Goodkin DE , Hartung H-P. , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis . Ann Neurol 2001; 50: 121-27.

13.

Rudick R. , Antel J. , Confavreux C. , Cutter G. , Ellison G. , Fischer J. et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 1997; 42: 379-82.

14.

Fisher E. , Cothren RM , Tkach JA , Masaryk TJ , Cornhill JF Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking . SPIE Medical Imaging 1997; 3034: 19-25.

15.

Rudick RA , Fisher E. , Lee J. -C, Simon J. , Jacobs L. , the Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS . Neurology 1999; 53: 1698-704.

16.

Besl PJ , McKay ND Method for registration of 3-D shapes . IEEE Patt Anal Machine Intell 1992; 14: 239-55.

17.

Besag J. On the statistical analysis of dirty pictures . J Roy Stat Soc 1986; 48: 259-302.

18.

Santago P. , Gage HD Statistical models of partial volume effect . IEEE Trans Image Proc 1995; 4: 1531-40.

19.

Rudick RA , Simonian NA , Alam JA , Campion M. , Scaramucci JO , Jones W. et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis . Neurology 1998 ; 50: 1266-72.

20.

Agresti A. An Introduction to Categorical Data Analysis. John Wiley & Sons , 1996.

21.

Clanet M. , Radue EW , Kappos L. , Hartung HP , Hohlfeld R. , Sandberg-Wollheim M. et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a (Avonex) in relapsing MS . Neurology 2002; 59: 1507-17.

22.

Fischer JS , Jak AJ , Knicker JE , Rudick RA , Cutter G. Multiple Sclerosis Functional Composite (MSFC). Administration and scoring manual: Unitech. National Multiple Sclerosis Society , 2001.

23.

Fox RJ , Lee J. -C, Rudick RA Optimal reference population for the Multiple Sclerosis Functional Composite . Mult Scler 2007; 13(7): 909-14.

24.

Fitzmaurice G. , Laird N. , Ware J. Applied Longitudinal Analysis. John Wiley & Sons , 2004.

25.

Weinblatt ME , Coblyn JS , Fox DA , Fraser PA , Holdsworth DE , Glass DN et al. Efficacy of low-dose methotrexate in rheumatoid arthritis . N Engl J Med 1985; 312: 818-22.

26.

Weinblatt ME , Trentham DE , Fraser PA , Holdsworth DE , Falchuk KR , Weissman BN et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis . Arthritis Rheum 1988; 31: 167-75.

27.

Flynn JA , Hellmann DB Methotrexate in rheumatoid arthritis: when NSAIDs fail . Cleve Clin J Med 1995; 62: 351-59.

28.

Tugwell P. , Pincus T. , Yocum D. , Stein M. , Gluck O. , Kraag G. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis . N Engl J Med 1995; 333: 137-41.

29.

O'Dell JR , Haire CE , Erikson N. , Drymalski W. , Palmer W. , Eckhoff PJ et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications . N Engl J Med 1996 ; 334: 1287-91.

30.

Moreland LW Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis . J Rheumatol 1996; 23(Suppl 44): 78-83.

31.

Boers M. , Verhoeven AC , Markusse HM , van de Laar Mafj , Westhovens R. , van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis . Lancet 1997; 350: 309-18.

32.

Maini RN , Breedveld FC , Kalden JR , Smolen JS , Davis D. , Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis . Arthritis Rheum 1998 ; 41: 1552-63.

33.

Weinblatt ME , Kremer JM , Bankhurst AD , Bulpitt KJ , Fleischmann RM , Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate . N Engl J Med 1999; 340: 253-59.

34.

Currier RD , Haerer AF , Meydrech EF Low dose oral methotrexate treatment of multiple sclerosis . J Neurol Neurosurg Psychiatry 1993; 56: 1217-18.

35.

Goodkin DE , Rudick RA , Medendorp SV , Daughtry MM , Schwetz KM , Fischer J. et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis . Ann Neurol 1995; 37: 30-41.

36.

Calabresi PA , Wilterdink JL , Rogg JM , Mills P. , Webb A. , Whartenby KA An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS . Neurology 2002; 58: 314-17.

37.

Sandoval DM , Alarcon GS , Morgan SL Adverse events in methotrexate-treated rheumatoid arthritis patients . Br J Rheumatol 1995; 34(Suppl 2): 49-56.

38.

Jones KW , Patel SR A family physician's guide to monitoring methotrexate . Am Fam Physician 2000; 62: 1607-14.

39.

Morgan SL , Baggott JE , Vaughn WH , Young PK , Austin JV , Krumdieck CL et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis . Arthritis Rheum 1990; 33: 9-18.

40.

Walker AM , Funch D. , Dreyer NA , Tolman KG , Kremer JM , Alarcon GS et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis . Arthritis Rheum 1993; 36: 329-35.

41.

Roenigk HH , Auerbach R. , Maibach HI , Weinstein GD Methotrexate in psoriasis: revised guidelines . J Am Acad Dermatol 1988; 19: 145-56.

42.

Kremer JM , Alarcon GS , Lightfoot RW , Willkens RF , Furst DE , Williams HJ et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity . Arthritis Rheum 1994; 37: 316-28.

43.

Kremer JM Not yet time to change the guidelines for monitoring methotrexate liver toxicity: they have served us well . J Rheumatol 2002 ; 29: 1590-92.

44.

Furst DE , Koehnke R. , Burmeister LF , Kohler J. , Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis . J Rheumatol 1989; 16: 313-20.

45.

Wilke WS , Biro JA , Segal AM Methotrexate in the treatment of arthritis and connective tissue disease . Cleve Clin J Med 1987; 54: 327-38.

46.

Fox RJ , Kinkel RP High-dose methylprednisolone in the treatment of multiple sclerosis . In Cohen JA , Rudick RA eds. Multiple Sclerosis Therapeutics, 3rd edition. London: Informa Healthcare , 2007: 515-33.

47.

Barkhof F. , Frequin Stfm , Hommes OR , Lamers K. , Scheltens P. , van Geel WJA et al. A correlative triad of gadolinium-DPTA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone . Neurology 1992; 42: 63-67.

48.

Frequin Stfm , Barkhof F. , Lamers KJB , Hommes OR The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis . J Neuroimmunol 1992; 40: 265-72.

49.

Richert ND , Ostuni JL , Bash CN , Leist TP , McFarland HF , Frank JA Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis . Mult Scler 2001; 7: 49-58.

50.

Goodkin DE , Kinkel RP , Weinstock-Guttman B. , VanderBrug Medendorp S. , Secic M. , Gogol D. et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis . Neurology 1998; 51: 239-45.

51.

Zivadinov R. , Rudick RA , De Masi R. , Nasuelli D. , Ukmar M. , Pozzi-Mucelli RS et al. Effects of IV methylprednisolone on brain atrophy in relapsingremitting MS . Neurology 2001; 57: 1239-47.

52.

Beck RW , Cleary PA , Anderson MM , Keltner JL , Shults WT , Kaufman DI et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis . N Engl J Med 1992 ; 326: 581-88.

53.

Beck RW , Cleary PA , Trobe JD , Kaufman DI , Kupersmith MJ , Paty DW et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis . N Engl J Med 1993; 329: 1764-9.

54.

Frequin Stfm , Lamers KJB , Barkhof F. , Borm GF , Hommes OR Follow-up study of MS patients treated with high-dose intravenous methylprednisolone . Acta Neurol Scand 1994; 90: 105-10.

55.

Gasperini C. , Pozzilli C. , Bastianello S. , Koudriavtseva T. , Galgani S. , Millefiorini E. et al. Effects of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing-remitting multiple sclerosis . Neurology 1998; 50: 403-6.

56.

Smith DR , Weinstock-Guttman B. , Cohen JA , Wei X. , Gutmann C. , Bakshi R. et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta . Mult Scler 2005; 11: 573-82.

57.

Cohen JA , Fischer JS , Bolibrush DM , Jak AJ , Kniker JE , Mertz LA et al. Intrarater and interrater reliability of the MS functional composite outcome measure . Neurology 2000; 54: 802-6.

58.

Cohen JA , Cutter GR , Fischer JS , Goodman AD , Heidenreich FR , Jak AJ et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial . Arch Neurol 2001; 58: 961-67.

59.

Solari A. , Radice D. , Manneschi L. , Motti L. , Montanari E. The multiple sclerosis functional composite: different practice effects in the three test components . J Neurol Sci 2005 ; 228: 71-74.